Resources
Practical guidance for biotech startups navigating NIH SBIR/STTR strategy, application development, reviewer expectations, and the broader non-dilutive funding landscape.
Checked September 12, 2026
NIH’s guidance explains how to assess ownership, key personnel, consultants, and research partners before applying, and what disclosures follow during Just-in-Time review.
NIH guidance ↗The revised policy caps covered submissions at nine per small business per fiscal year: new and resubmission Phase I, Fast-Track, and Direct to Phase II applications and contract proposals. This notice replaces the April guidance.
NIH · NOT-OD-26-090 ↗PA-27-100 supports eligible small businesses pursuing Phase I, Phase II, Direct to Phase II, or Fast-Track funding. The next listed deadline is January 5, 2027; visit the Funding page for review and potential start dates.
Official funding announcement ↗Award size, competition, preparation costs, and timing: assessing whether an NIH SBIR/STTR application is worth pursuing.
Read insight →Federal agency budgets, NIH award mechanisms and success rates, and related non-dilutive funding pathways.
Read insight →Evidence for follow-on investment, technical feedback, and planning benefits beyond the award.
Read insight →Research plans, registration dependencies, university coordination, and NIH submission requirements.
Read insight →How to interpret reviewer concerns and decide whether another application is justified.
Read insight →HHS foreign-risk criteria, pre-award screening, and continuing disclosure obligations.
Read insight →Your next funding decision
Tell us what your company is pursuing, where you are in the process, and what decision or review you need help with.
Discuss your funding strategy